Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiac Cath Lab Staff Radiation Exposure (SAFE-T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03959072
Recruitment Status : Recruiting
First Posted : May 22, 2019
Last Update Posted : January 8, 2021
Sponsor:
Information provided by (Responsible Party):
Corindus Inc.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this randomized safety and observational study is to demonstrate CorPath GRX chronic total occlusion PCI is safe, and that Cardiac Catheterization Laboratory staff have no additional exposure to radiation when compared to conventional manual chronic total occlusion PCI procedures without added procedure time.

Condition or disease Intervention/treatment
Coronary Artery Disease Chronic Total Occlusion of Coronary Artery Percutaneous Coronary Intervention Device: Robotic CTO PCI Procedure: Conventional (Manual) CTO PCI

Detailed Description:
This is prospective, dual-arm, randomized, multi-center, observational study comparing patient outcomes and staff radiation exposure in chronic total occlusion PCI procedures through 48 hours post procedure or hospital discharge, whichever occurs first.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cardiac Cath Lab Staff Radiation Exposure During Chronic Total Occlusion PCI: CorPath GRX vs. Manual
Actual Study Start Date : September 5, 2019
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Robotic Chronic Total Occlusion PCI
The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
 Device: Robotic CTO PCI
Randomized to robotic CTO PCI.
Other Name: CorPath GRX System
Conventional (manual) Chronic Total Occlusion PCI
The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
 Procedure: Conventional (Manual) CTO PCI
Randomized to manual CTO PCI.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinical Success [ Time Frame: 48 hours ]
    Defined as successful CTO PCI revascularization with achievement of <30% residual diameter stenosis (visual estimate) within the treated segment and restoration of antegrade TIMI grade 3 flow, without in-hospital major adverse events (MAE).

  2. In-hospital Major Adverse Events (MAE) [ Time Frame: 48 hours ]
    Number of MAE events that occurs within 48 hours of the CTO PCI procedure or hospital discharge, whichever occurs first.


Secondary Outcome Measures :
  1. Operator Radiation Exposure [ Time Frame: Procedure ]
    Cumulative dose the physician receives as recorded from electronic pocket dosimeter during procedure.

  2. Staff Radiation Exposure [ Time Frame: Procedure ]
    Cumulative dose the staff receives as recorded from electronic pocket dosemeter during procedure.

  3. Patient Radiation Exposure [ Time Frame: Procedure ]
    DAP (dose-area-product) and cumulative dose/air kerma as recorded during the procedure

  4. Fluoroscopy Time [ Time Frame: Procedure ]
    Total fluoroscopy (min.) utilized during the procedure as recorded by an Imaging System.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Subjects >18 years of age with symptoms suggestive of ischemic heart disease, with TIMI grade 0 flow and a lesion that is thought to be present for more than 3 months.
Criteria

Inclusion Criteria:

  • CTO lesion, successfully crossed with conventional manual techniques;
  • The Investigator deems the procedure appropriate for robotic-assisted CTO PCI with the CorPath GRX System;
  • Individual monitoring of radiation dose, using the pocket dosimeter, was initiated at start of procedure;
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria:

  • Failure/inability/unwillingness to provide informed consent, or
  • Cardiogenic Shock; or
  • Perforation which requires treatment (e.g. covered stent, coil and other embolization techniques, or pericardiocentesis).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959072


Contacts
Layout table for location contacts
Contact: Tina M. Ridgeway, BS, RN (757) 810-5166 tina.ridgeway@corindus.com
Contact: John Van Vleet, MS (260) 615-8892 john.vanvleet@corindus.com

Locations
Layout table for location information
United States, Missouri
St. Luke's Hospital of Kansas City Recruiting
Kansas City, Missouri, United States, 64111
Contact: Rosann Gans, RN    816-932-6122    rgans@saint-lukes.org   
Principal Investigator: Adam Salisbury, MD         
United States, Pennsylvania
WellSpan York Hospital Completed
York, Pennsylvania, United States, 17405
United States, Washington
University of Washington Not yet recruiting
Seattle, Washington, United States, 98195
Contact: Kamilah Taylor    206-221-2142    kit2@cardiology.washington.edu   
Principal Investigator: William Lombardi, MD         
Sponsors and Collaborators
Corindus Inc.
Investigators
Layout table for investigator information
Principal Investigator: William Lombardi (Acting), MD University of Washington
Principal Investigator: William Nicholson (Emeritus), MD WellSpan York Hospital
  Study Documents (Full-Text)

Documents provided by Corindus Inc.:
Study Protocol  [PDF] February 8, 2020

More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Corindus Inc.
ClinicalTrials.gov Identifier: NCT03959072    
Other Study ID Numbers: 104-08553
First Posted: May 22, 2019    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Data will be available 12 months after study completion.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
 Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases